Whats new

Whats new.

Baird - Collab with Merck Provides Downside Support Ahead of Phase 2 HNSCC Data; Maintain OP, $7 PT (Analyst: Joel L. Beatty, MD)

June 6th 2024

For a copy of this research report please contact your Baird advisor

Go back